Expression of LC3-I, LC3-II & Beclin 1 in Vitiligo

Autophagy Clinical Trial

Official title:

Expression of LC3-I, LC3-II & Beclin 1 in Vitiligo and Healthy Control; Comparative Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03371758
• Other study ID #: Dermatology
• Status: Recruiting
• Phase: N/A
• First received: December 5, 2017
• Last updated: January 19, 2018
• Start date: January 2017
• Est. completion date: May 2018

Study information

• Verified date: January 2018
• Source: Cairo University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The exact mechanism of impairment of autophagy in vitiligo has not yet been determined.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 40
• Est. completion date: May 2018
• Est. primary completion date: May 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 12 Years and older

Eligibility

Inclusion Criteria:

• • Patients with non-segmental vitiligo whether active or stable.

• Age above 12 years.

• Both sexes.

Exclusion Criteria:

• • Patients should not use any topical or systemic treatment at least 6 weeks before inclusion into the study.

• Patients having other autoimmune disease, heart disease, liver disease, kidney disease, neurological disorder, cancer, active infection or any chronic disease.

• Pregnancy or breast feeding for female patients.

Related Conditions & MeSH terms

• Autophagy
• Vitiligo

Intervention

Other:
• skin biopsy
Punch skin biopsy will be taken from the lesional and non-lesional skin of vitiligo patients as well as healthy skin of controls.

Locations

Country	Name	City	State
Egypt	Maha Fathy Elmasry	Cairo

Sponsors (1)

Lead Sponsor	Collaborator
Cairo University

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Expression of LC3-I, LC3-II & Beclin 1 in vitiligo patients		1 year